Suppr超能文献

非酒精性脂肪性肝病与肥胖:肠道细菌的作用。

Non-alcoholic fatty liver disease and obesity: the role of the gut bacteria.

机构信息

Institute of Medical Science, University of Toronto, Toronto, ON, Canada.

Toronto General Hospital, University Health Network, 585 University Avenue, 9-973, Toronto, ON, M5G 2C4, Canada.

出版信息

Eur J Nutr. 2019 Aug;58(5):1771-1784. doi: 10.1007/s00394-018-1844-5. Epub 2018 Oct 10.

Abstract

Non-alcoholic fatty-liver disease (NAFLD) is now considered one of the leading causes of liver disease worldwide and is associated with metabolic syndrome and obesity. There are several factors contributing to the disease state. Recent research suggests that the intestinal microbiota (IM) and bacterial products may play a role through several mechanisms which include increased energy uptake, intestinal permeability and chronic inflammation. In addition to diet and exercise, treatment options targeting the IM are being investigated and include the use of pre-, pro- and synbiotics as well as the possibility of fecal microbial transfers. This literature review explores the relationship between NAFLD and the IM as well as highlight new IM treatment options that may become available in the near future.

摘要

非酒精性脂肪性肝病(NAFLD)现已被认为是全球范围内导致肝病的主要原因之一,与代谢综合征和肥胖有关。有几个因素促成了这种疾病状态。最近的研究表明,肠道微生物群(IM)和细菌产物可能通过多种机制发挥作用,包括增加能量摄取、肠道通透性和慢性炎症。除了饮食和运动之外,还在研究针对 IM 的治疗选择,包括使用预、益生菌和合生元,以及粪便微生物转移的可能性。本文献综述探讨了 NAFLD 与 IM 之间的关系,并强调了可能在不久的将来出现的新的 IM 治疗选择。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验